Quick Facts
Paradigm shifting immunotherapy
For complex, unmet clinical need indications
Advanced clinical-stage pipeline
with promising phase 2a results
Multi-billion dollar
underserved markets
Bone-Marrow Transplantations Sepsis | Solid Tumors
Short regulatory approval pathway
FDA & EU orphan designations; Specialized life-threatening regulation in Europe potentially enabling post-Phase II marketing approval
Strong leadership
Previously founded and managed PROLOR Biotech, sold For $560M; Signed partnership with Pfizer, $295 Million down payment
Cash balance
$30 Million invested; Cash balance supporting multiple clinical milestone within 12-24 months
Latest news & events
SEC Filings
| Date | Form | Description | Download |
|---|---|---|---|
| March 27, 2019 | 6-K | Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange | |
| Feb 19, 2019 | 6-K | Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange | |
| Nov 19, 2018 | 6-K | Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange |
Corporate Governance
| Charter of the Audit Committee of the Board of Directors | download |
| Charter of the Compensation Committee of the Board of Directors | download |
| Code of Business Conduct and Ethics | download |
| Disclosure Policy | download |
| Employee Complaint Procedures for Accounting and Auditing Matters | download |
| Insider Trading Policy | download |
Subscribe to our newsletter
Find out more
14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072 | F +972.2.6708070
info@enlivex.com